Crescent Biopharma
CBIO
36 hedge funds and large institutions have $230M invested in Crescent Biopharma in 2014 Q1 according to their latest regulatory filings, with 36 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$104M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$29.6M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$10.8M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$5.68M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$2.87M |
Top Sellers
CBIO Hedge Fund Activity: Q1 2014 in Review
36 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q1 2014, worth a combined $230M.
Buyers outnumbered sellers: 36 funds opened new CBIO positions and 0 closed out — a net gain of 36 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $104M.
- 36 institutional investors held Crescent Biopharma (CBIO) as of Q1 2014, up from 0 in Q4 2013.
- Funds reported $230M of Crescent Biopharma stock for Q1 2014.
- 36 funds opened new Crescent Biopharma positions in Q1 2014 and 0 closed out, a net change of +36 holders.
- The largest Crescent Biopharma buyer in Q1 2014 was NEA Management Company, an estimated $104M added.
Based on aggregated 13F filings for Q1 2014.